Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. 2015

Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, People's Republic of China.

A novel series of benzo[a]phenazin derivatives bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerases inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549). These compounds were found to be dual inhibitors of topoisomerase (Topo) I and Topo II, and exhibited excellent antiproliferative activity, in particular against HL-60 cells with submicromolar IC50 values. Further mechanistic studies showed that this class of compounds acted as Topo I poisons by stabilizing the Topo I-DNA cleavage complexes and Topo II catalytic inhibitors by inhibiting the ATPase activity of hTopo II. Molecular docking studies revealed the binding modes of these compounds for Topo I and Topo II.

UI MeSH Term Description Entries
D010619 Phenazines
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000588 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
February 2016, Bioorganic & medicinal chemistry letters,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
January 2012, European journal of medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
June 2013, Organic & biomolecular chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
August 2008, Journal of medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
June 2011, European journal of medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
July 2022, European journal of medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
May 2022, Bioorganic chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
November 2016, Bioorganic & medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
February 2024, European journal of medicinal chemistry,
Bing-Lei Yao, and Yan-Wen Mai, and Shuo-Bin Chen, and Hua-Ting Xie, and Pei-Fen Yao, and Tian-Miao Ou, and Jia-Heng Tan, and Hong-Gen Wang, and Ding Li, and Shi-Liang Huang, and Lian-Quan Gu, and Zhi-Shu Huang
January 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!